Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients
Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients
复制标题
DOI：
10.1016/j.cca.2018.03.019
复制
发表时间：
2018-07-01
影响因子：
5
通讯作者：
Vanamail, Perumal
中科院分区：
文献类型：
--
作者：
Dalal, Venus;Kumar, Raman;Vanamail, Perumal
背景资料：卵巢癌的死亡率显著较高，主要是由于初始病程期间的无症状行为，并且在诊断时大多数患者已经进展到晚期。上皮性卵巢癌（EOC）腹水中的脱细胞成分被认为可以通过提供肿瘤细胞增殖的微环境来促进肿瘤细胞的生长。方法：采用双抗体夹心酶联免疫吸附法（ELISA）检测30例EOC患者和15例正常对照者腹水中IL-6和VEGF-A的水平。他们的水平与临床病理特征和生物标志物的潜力进行了assessed.Results和结论：卵巢癌患者表现出显着较高的水平IL-6（中位数-5636 pg/ml）和VEGF-A（中位数-4556 pg/ml）在腹水相比，对照组。IL-6和VEGF-A水平与临床病理参数显著相关。IL-6和VEGF-A的ROC曲线显示了绝对的敏感性和特异性组合。Kaplan Meier分析表明，IL-6和VEGF-A水平升高与无进展生存期缩短显著相关。因此，本研究揭示了IL-6和VEGF-A具有很大的潜力，在更大的患者队列中验证后，在未来用作无进展生存的上级生物标志物。
Background: Ovarian cancer is represented with significantly higher mortality rate predominately due to asymptomatic behaviour during initial disease course and at diagnosis majority patients already progressed to advanced stage. Acellular fraction of ascites in epithelial ovarian cancer (EOC) has been suggested to promote growth of tumor cells by providing ambient micro-environment for their proliferation. This acellular fraction contains multiple growth factors including IL-6 and VEGF-A, which were exploited to establish their bio-marker significance in EOC patients.Methods: IL-6 and VEGF-A levels in ascitic fluid of 30 EOC patients and 15 controls were measured using high sensitivity sandwich enzyme linked immune sorbent (ELISA) assay. Their levels were correlated with clinicopathological characteristics and bio-marker potential was assessed.Results and conclusion: EOC patients showed significantly higher levels for IL-6 (median-5636 pg/ml) and VEGF-A (median-4556 pg/ml) in ascitic fluid compared to controls. Levels of IL-6 and VEGF-A significantly correlated with clinico-pathological parameters. ROC curves of IL-6 and VEGF-A showed absolute combination of sensitivity and specificity. Kaplan Meier analysis demonstrated that higher levels of IL-6 and VEGF-A were significantly associated with shorter progression free survival. Thus, this study revealed that IL-6 and VEGF-A have great potential to be used as superior bio-markers for progression free survival in future after validation in larger patients' cohort.